Empagliflozin Started Within 72 Hours of a Heart Attack Improved Cardiac Biomarkers and Echocardiographic Parameters at 26 Weeks

The SGLT2 inhibitor drug class has reshaped treatment of heart failure and type 2 diabetes, but the question of whether these drugs offer benefit when started immediately after acute MI — before heart failure has established itself — remained largely open when the Empagliflozin in patients with acute Myocardial infarction (EMMY) trial was designed. It is a question with real clinical stakes: MI is a major cause of incident heart failure, with roughly a 15% event rate within 12 months. If early SGLT2 inhibition protects the myocardium during the remodeling window that follows a large infarct, the implications for how cardiologists manage the post-MI period are meaningful.

EMMY was an academic, multicenter, double-blind trial that enrolled 476 patients with acute MI accompanied by a large creatine kinase elevation greater than 800 IU/L — a threshold roughly four times the upper limit of normal, selecting for large, hemodynamically significant infarcts. Patients were randomized to empagliflozin 10mg or matching placebo once daily within 72 hours of percutaneous coronary intervention. The primary outcome was change in NT-proBNP, a biomarker reflecting cardiac wall stress, over 26 weeks. Secondary outcomes included echocardiographic parameters: left ventricular ejection fraction, left ventricular end-systolic and end-diastolic volumes, and E/e′ as a measure of diastolic function.

NT-proBNP reduction was 15% greater in the empagliflozin group after adjusting for baseline NT-proBNP, sex, and diabetes status (95% CI -4.4% to -23.6%, P = 0.026). On echocardiography, absolute left ventricular ejection fraction improvement was 1.5 percentage points greater in the empagliflozin group (95% CI 0.2 to 2.9%, P = 0.029). Left ventricular end-systolic volume was lower by 7.5 mL (95% CI 3.4 to 11.5 mL, P = 0.0003) and end-diastolic volume by 9.7 mL (95% CI 3.7 to 15.7 mL, P = 0.0015). Mean E/e′ reduction was 6.8% greater in the empagliflozin group. Seven patients were hospitalized for heart failure across both groups — three in the empagliflozin group and four in the placebo group — but the trial was not powered to detect differences in clinical events.

• —NT-proBNP and echocardiographic changes are surrogate endpoints. The trial was not powered or designed to detect differences in clinical outcomes.
• —The creatine kinase greater than 800 IU/L enrollment threshold selected for large infarcts. Results may not apply to smaller MIs or patients without significant left ventricular dysfunction following percutaneous coronary intervention.
• —Echocardiographic measurement, even with core laboratory adjudication, carries inherent inter- and intra-observer variability that can influence secondary endpoint results.
• —The 26-week follow-up period is short for evaluating the longer-term trajectory of left ventricular remodeling post-MI.

EMMY makes a biologically plausible case that early SGLT2 inhibition after large MI reduces cardiac stress and improves structural remodeling in the weeks that follow. It does not make a clinical case that it prevents hospitalizations or saves lives — EMPACT-MI addressed that question at scale, and the answer was negative. The mechanistic signal from EMMY remains genuinely interesting. Whether it eventually translates to a defined clinical role for early SGLT2 inhibition post-MI depends on trials with harder endpoints that have not yet been completed.